16.42
-0.36 (-2.15%)
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Bullish | Bullish |
Biotechnology (Global) | Bullish | Bullish | |
Stock | Enliven Therapeutics, Inc. | Bullish | Bullish |
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven’s programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations. |
|
Sector | Healthcare |
Industry | Biotechnology |
Ownership
Name | Date | Shares Held |
---|---|---|
5Am Venture Management, Llc | 31 Dec 2023 | 5,160,975 |
52 Weeks Range |
9.80 - 26.00
|
|
High | 34.00 (Mizuho, 107.06%) | Buy |
Median | 34.00 (107.06%) | |
Average | 34.00 (107.06%) | |
Total | 1 Buy |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Mizuho | 09 Apr 2024 | 34.00 (107.06%) | Buy | 19.19 |
No data within this time range.
Date | Type | Details |
---|---|---|
11 Apr 2024 | Announcement | Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia |
09 Apr 2024 | Announcement | Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors |
28 Mar 2024 | Announcement | Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024 |
19 Mar 2024 | Announcement | Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates |
14 Mar 2024 | Announcement | Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update |
27 Feb 2024 | Announcement | Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference |
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |